IQVIA (NYSE:IQV) Issues Quarterly Earnings Results, Misses Estimates By $0.21 EPS

IQVIA (NYSE:IQV) announced its earnings results on Thursday. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21), Zacks reports. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. IQVIA updated its FY 2025 guidance to 11.700-12.100 EPS.

IQVIA Price Performance

Shares of NYSE:IQV opened at $208.13 on Friday. IQVIA has a 12 month low of $187.62 and a 12 month high of $261.73. The firm has a market capitalization of $37.78 billion, a P/E ratio of 27.75, a P/E/G ratio of 2.25 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.81. The company’s fifty day moving average price is $200.67 and its 200 day moving average price is $219.54.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on IQV. Bank of America lowered their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Morgan Stanley dropped their price target on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. JPMorgan Chase & Co. reduced their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Finally, Leerink Partners reiterated an “outperform” rating and set a $248.00 price target (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $252.39.

Insider Buying and Selling at IQVIA

In other news, Director John G. Danhakl purchased 1,275 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were purchased at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the purchase, the director now directly owns 1,275 shares of the company’s stock, valued at $255,739.50. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.60% of the stock is currently owned by insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.